David D. Kim, PhD, is an Assistant Professor of Medicine and Public Health Sciences at the University of Chicago. His interdisciplinary research integrates health economics, policy evaluation, and decision modeling to advance value-based healthcare decisions. Dr. Kim has made significant contributions in three core research areas: (1) evaluating long-term health outcomes, economic impacts, and equity implications of health interventions to guide evidence-informed policy; (2) developing rigorous methodological approaches in economic evaluation and research prioritization to optimize healthcare resource allocation; (3) identifying geographic and racial disparities in the use of low-value healthcare services to inform targeted policy interventions and resource reallocation strategies. Dr. Kim’s extensive publication record includes over 60 peer-reviewed articles in prominent journals such as JAMA, Annals of Internal Medicine, Health Affairs, and Medical Decision Making. He has developed innovative analytical tools and disease simulation models, notably the Criteria for Health Economic Quality Evaluation (CHEQUE) tool and the Diabetes, Obesity, Cardiovascular Disease Microsimulation (DOC-M) model. His research frequently informs broader public discourse, having been featured in leading media outlets including The New York Times and The Washington Post. Dr. Kim provides strategic guidance to prominent national and international advisory groups, including the World Health Organization’s Guidelines Development Group, the Institute for Clinical and Economic Review (ICER), and currently serves as a Methods Consultant for the Annals of Internal Medicine.
University of Washington
Seattle
PhD - Health Economics
2016
University of Michigan
Ann Arbor
MS - Biostatistics
2012
University of Michigan
Ann Arbor
BSE - Biomedical Engineering
2009
Fiscal Impact of Expanded Medicare Coverage for GLP-1 Receptor Agonists to Treat Obesity.
Fiscal Impact of Expanded Medicare Coverage for GLP-1 Receptor Agonists to Treat Obesity. JAMA Health Forum. 2025 Apr 04; 6(4):e250905.
PMID: 40279111
Estimated Impact Of Medically Tailored Meals On Health Care Use And Expenditures In 50 US States.
Estimated Impact Of Medically Tailored Meals On Health Care Use And Expenditures In 50 US States. Health Aff (Millwood). 2025 Apr; 44(4):433-442.
PMID: 40193837
Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults.
Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults. JAMA Health Forum. 2025 Mar 07; 6(3):e245586.
PMID: 40085108
Genicular Artery Embolization, Radiofrequency Ablation, and Corticosteroid Therapy for Knee Osteoarthritis: A Cost-Effectiveness Analysis Using Randomized Clinical Trial Data.
Genicular Artery Embolization, Radiofrequency Ablation, and Corticosteroid Therapy for Knee Osteoarthritis: A Cost-Effectiveness Analysis Using Randomized Clinical Trial Data. AJR Am J Roentgenol. 2024 Dec 26; 1-15.
PMID: 39320355
Cataloging health state utility estimates for Duchenne muscular dystrophy and related conditions.
Cataloging health state utility estimates for Duchenne muscular dystrophy and related conditions. Health Qual Life Outcomes. 2024 Sep 02; 22(1):72.
PMID: 39218902
The effects of SNAP emergency allotments on state-level SNAP benefits and enrollment during the COVID-19 pandemic.
The effects of SNAP emergency allotments on state-level SNAP benefits and enrollment during the COVID-19 pandemic. Health Aff Sch. 2024 Sep; 2(9):qxae109.
PMID: 39328393
An efficient approach to expand equitable access to antiobesity medications: deprescribing after weight loss plateau.
An efficient approach to expand equitable access to antiobesity medications: deprescribing after weight loss plateau. Am J Manag Care. 2024 Aug; 30(8):348-350.
PMID: 39146483
Patient-Provider Communication and Access, Use, and Financial Burden of Care.
Patient-Provider Communication and Access, Use, and Financial Burden of Care. Am J Prev Med. 2024 Nov; 67(5):740-745.
PMID: 39002888
Out-of-pocket costs for diagnostic testing following abnormal prostate cancer screening among privately insured men.
Out-of-pocket costs for diagnostic testing following abnormal prostate cancer screening among privately insured men. Cancer. 2024 Oct 01; 130(19):3305-3310.
PMID: 39005006
Balancing innovation and affordability in anti-obesity medications: the role of an alternative weight-maintenance program.
Balancing innovation and affordability in anti-obesity medications: the role of an alternative weight-maintenance program. Health Aff Sch. 2024 Jun; 2(6):qxae055.
PMID: 38828004